STOCK TITAN

Schedule 13D/A: NEA Reports 1.63M MRKR Shares, 12.6% Ownership After Dilution

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Marker Therapeutics Schedule 13D Amendment No. 4 reports that a group of New Enterprise Associates entities and named managers collectively beneficially own 1,625,678 shares of Marker Therapeutics common stock, representing 12.6% of the 12,938,910 shares reported outstanding as of August 4, 2025. The Amendment states the reported ownership percentage decreased by more than 1% solely because the number of outstanding shares increased. The reporting persons disclaim beneficial ownership except for shares held of record and say NEA 16 acquired its shares for investment purposes. No transactions were effected by the reporting persons in the last 60 days and they state no present plans to pursue extraordinary corporate actions.

Positive

  • Transparent disclosure of beneficial ownership and cause of percentage change (increase in shares outstanding).
  • Significant stake disclosed: 1,625,678 shares representing 12.6% of outstanding common stock, providing clarity to the market.
  • No transactions in the last 60 days, reducing uncertainty about imminent position changes.

Negative

  • Ownership diluted by an increase in outstanding shares, causing a decrease in reported percentage ownership by more than 1%.
  • No commitment to active support or engagement: reporting persons state no plans for board changes, asset sales, or other corporate actions.

Insights

TL;DR NEA group holds a notable 12.6% stake; change driven by dilution, not disposals.

The filing clarifies ownership across NEA 16, NEA Partners 16, NEA 16 GP, LLC and named managers totaling 1,625,678 shares, calculated against 12,938,910 outstanding shares as of August 4, 2025. Importantly, the decrease in percentage ownership is attributed explicitly to an increase in shares outstanding rather than share sales. The position remains described as investment-oriented with no recent transactions in the past 60 days. For investors, this is a transparency filing without announced strategic actions or board changes that would materially alter Marker Therapeutics' operations.

TL;DR Disclosure is routine and compliant; no governance actions or control intent disclosed.

The Amendment reiterates that the Reporting Persons have no present plans to change board composition, pursue mergers, transfer material assets, alter capitalization, or seek delisting. The filing includes a joint filing agreement and a power of attorney as exhibits. Managers disclaim beneficial ownership beyond record holdings. From a governance perspective, this indicates no immediate activist or control-driven governance campaign by the NEA group based on the information disclosed.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


New Enterprise Associates 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:08/18/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/18/2025
NEA Partners 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:08/18/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/18/2025
NEA 16 GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:08/18/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/18/2025
Forest Baskett
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
Date:08/18/2025
Ali Behbahani
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
Date:08/18/2025
Carmen Chang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
Date:08/18/2025
Anthony A. Florence, Jr.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr.
Date:08/18/2025
Mohamad H. Makhzoumi
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:08/18/2025
Scott D. Sandell
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
Date:08/18/2025
Paul Walker
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
Date:08/18/2025
Comments accompanying signature:
This Amendment No. 4 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

What stake does NEA report in Marker Therapeutics (MRKR)?

The NEA reporting persons state beneficial ownership of 1,625,678 shares, equal to 12.6% of 12,938,910 shares outstanding as of August 4, 2025.

Why did NEA's reported percentage ownership in MRKR change?

The Amendment states the percentage decreased by more than 1% due to an increase in the number of outstanding shares, not because of share sales by the reporting persons.

Has NEA disclosed any plans to seek control or change Marker Therapeutics' management?

No. The reporting persons explicitly state they have no present plans to change the board, pursue mergers, sell material assets, alter capitalization, or take similar actions.

Did the reporting persons trade MRKR shares recently?

According to the filing, none of the Reporting Persons effected any transaction in the last 60 days.

What exhibits are included with the Schedule 13D Amendment No. 4?

The filing lists Exhibit 1 (agreement regarding joint Schedule 13D filing) and Exhibit 2 (power of attorney regarding filings under the Exchange Act).
Marker Therapeut

NASDAQ:MRKR

View MRKR Stock Overview

MRKR Rankings

MRKR Latest News

MRKR Latest SEC Filings

MRKR Stock Data

21.68M
15.76M
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON